Arrestins in Bone - Progress in Molecular Biology and Translational Science - page 346

43. Dean T, Linglart A, Mahon MJ, et al. Mechanisms of ligand binding to the parathyroid
hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1 - 15)
radioligand for G{alpha}S-coupled receptor conformations. Mol Endocrinol .

2006;20:931 - 943.
44. Jouishomme H, Whitfield JF, Gagnon L, et al. Further definition of the protein kinase
C activation domain of the parathyroid hormone. J Bone Miner Res . 1994;9:943- 949.
45. Whitfield JF, Morley P. Small bone-building fragments of parathyroid hormone: new
therapeutic agents for osteoporosis. Trends Pharmacol Sci . 1995;16:382- 386.
46. Wei H, Ahn S, Shenoy SK, et al. Independent beta-arrestin 2 and G protein-mediated
pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2.
Proc Natl Acad Sci USA . 2003;100:10782- 10787.
47. Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte func-
tion and growth. Endocr Rev . 1992;13:596 - 611.
48. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor confor-
mation. FASEB J . 2001;15:598- 611.
49. Brzostowski JA, Kimmel AR. Signaling at zero G: G-protein-independent functions for
7-TM receptors. Trends Biochem Sci . 2001;26:291 - 297.
50. Kenakin T. Functional selectivity through protean and biased agonism: who steers the
ship? Mol Pharmacol . 2007;72:1393- 1401.
51. Gesty-Palmer D, Luttrell LM. Heptahelical terpsichory. Who calls the tune? J Recept Sig-
nal Transduct Res . 2008;28:39- 58.
52. Violin JD, Lefkowitz RJ. [beta]-Arrestin-biased ligands at seven transmembrane recep-
tors. Trends Pharmacol Sci . 2007;28:416- 422.
53. Lefkowitz RJ. G protein-coupled receptor kinases. Cell . 1993;74:409 - 412.
54. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in
receptor desensitization and signaling. Pharmacol Rev . 2001;53:1 - 24.
55. Luttrell LM, Ferguson SS, Daaka Y, et al. Beta-arrestin-dependent formation of beta2
adrenergic receptor-Src protein kinase complexes. Science . 1999;283:655- 661.
56. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. Beta-
arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intra-
cellular targeting of activated ERK1/2. J Cell Biol . 2000;148:1267 - 1281.
57. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. beta-Arrestins and cell signaling. Annu
Rev Physiol . 2007;69:483 - 510.
58. Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular
signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA . 2001;98:
2449- 2454.
59. McDonald PH, Chow CW, Miller WE, et al. Beta-arrestin 2: a receptor-regulated
MAPK scaffold for the activation of JNK3. Science . 2000;290:1574- 1577.
60. Rey A, Manen D, Rizzoli R, Caverzasio J, Ferrari SL. Proline-rich motifs in the para-
thyroid hormone (PTH)/PTH-related protein receptor C terminus mediate scaffolding
of c-Src with beta-Arrestin2 for ERK1/2 activation.

J Biol Chem . 2006;281:

38181- 38188.
61. Shenoy SK, Lefkowitz RJ. Seven-transmembrane receptor signaling through {beta}-
arrestin. Sci STKE . 2005;308:cm10.
62. Azzi M, Charest PG, Angers S, et al. Beta-arrestin-mediated activation of MAPK by
inverse agonists reveals distinct active conformations for G protein-coupled receptors.
Proc Natl Acad Sci USA . 2003;100:11406- 11411.
63. Gesty-Palmer D, Chen M, Reiter E, et al. Distinct beta-arrestin- and G protein-
dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation.
J Biol Chem . 2006;281:10856- 10864.
64. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone
increases bone formation in adult rats by activation of bone lining cells. Endocrinology .
1995;136:3632- 3638.